FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US New asthma indication for Trelegy Ellipta introduces an important ...
Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) is a prescription drug that’s used to treat COPD and asthma. Trelegy Ellipta comes as an inhaler. To learn ...
New asthma indication for Trelegy Ellipta introduces an important option for patients to the current treatment paradigm The FDA-approved strength for both COPD and asthma is fluticasone furoate / ...
Some people with asthma need to use multiple inhaled medicines each day to keep their symptoms under control. The approval of long-acting, combination inhalers that contain more than one medicine is ...
LONDON & BURLINGAME, Calif.--(BUSINESS WIRE)--GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication ...
Sept 9 (Reuters) - GlaxoSmithKline Plc (GSK.L), opens new tab said on Wednesday the U.S health regulator approved its lung disease drug Trelegy Ellipta for expanded use, making it the first inhaler ...
Some people with chronic obstructive pulmonary disease (COPD) need to use multiple inhaled medicines each day to control their symptoms. Long-acting combination inhalers that contain more than one ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved Trelegy Ellipta, once-daily, single-inhaler triple therapy, for the new indication of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback